53516-95-3

Upstream product

• 121-02-8 2-methyl-5-nitrobenzene-1-sulfonyl chloride 

Downstream Products

• 945619-40-9 N'-((6-bromoimidazo[1,2-a]pyridin-3-yl)methylene)-2-methyl-5-nitrobenzenesulfonohydrazide 
• 1101118-13-1 N'-((5-methoxypyrazolo[1,5-a]pyridin-3-yl)methylene)-N,2-dimethyl-5-nitrobenzenesulfonohydrazide 
• 1101118-71-1 N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-2-methyl-5-nitrobenzenesulfonohydrazide 
• 1356145-57-7 N'-(1-(5-cyanopyrazolo[1,5-a]pyridin-3-yl)ethylidene)-2-methyl-5-nitrobenzenesulfonohydrazide 
• 1356145-71-5 N'-(1-(5-bromopyrazolo[1,5-a]pyridin-3-yl)ethylidene)-N,2-dimethyl-5-nitrobenzenesulfonohydrazide 
• 1356145-63-5 N'-(1-(5-bromopyrazolo[1,5-a]pyridin-3-yl)ethylidene)-2-methyl-5-nitrobenzenesulfonohydrazide 
• 1356145-61-3 N'-(1-(5-cyanopyrazolo[1,5-a]pyridin-3-yl)butylidene)-2-methyl-5-nitrobenzenesulfonohydrazide 
• 1356145-67-9 N'-(1-(5-cyanopyrazolo[1,5-a]pyridin-3-yl)propylidene)-N,2-dimethyl-5-nitrobenzenesulfonohydrazide 
• 1356145-59-9 N'-(1-(5-cyanopyrazolo[1,5-a]pyridin-3-yl)propylidene)-2-methyl-5-nitrobenzenesulfonohydrazide 
• 1356145-65-7 N'-(1-(5-cyanopyrazolo[1,5-a]pyridin-3-yl)ethylidene)-N,2-dimethyl-5-nitrobenzenesulfonohydrazide 
• 1101118-75-5 N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-N-ethyl-2-methyl-5-nitrobenzenesulfonohydrazide 
• 1101118-83-5 N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-2-methyl-5-nitro-N-(2-(piperidin-1-yl)ethyl)benzenesulfonohydrazide 
• 1101118-81-3 N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-2-methyl-N-(2-morpholinoethyl)-5-nitrobenzenesulfonohydrazide 
• 1101118-77-7 N'-((5-cyanopyrazolo[1,5-a]pyridin-3-yl)methylene)-N-(2-(diethylamino)ethyl)-2-methyl-5-nitrobenzenesulfonohydrazide 

Relevant academic research and scientific papers

Synthesis, in vitro α-amylase inhibitory, and radicals (DPPH & ABTS) scavenging potentials of new N-sulfonohydrazide substituted indazoles

Over-expression of α-amylase enzyme causes hyperglycemia which lead to many physiological complications including oxidative stress, one of the most commonly associated problem with diabetes mellitus. Marketed α-amylase inhibitors such as acarbose, voglibose, and miglitol used to treat type-II diabetes mellitus, but also linked to several harmful effects. Therefore, it is essential to explore new and nontoxic antidiabetic agents with additional antioxidant properties. In this connection, a series of new N-sulfonohydrazide substituted indazoles 1–19 were synthesized by multistep reaction scheme and assessed for in vitro α-amylase inhibitory and radical (DPPH and ABTS) scavenging properties. All compounds were fully characterized by different spectroscopic techniques including 1H, 13C NMR, EI-MS, HREI-MS, ESI-MS, and HRESI-MS. Compounds showed promising α-amylase inhibitory activities (IC50 = 1.23 ± 0.06–4.5 ± 0.03 μM) as compared to the standard acarbose (IC50 1.20 ± 0.09 μM). In addition to that all derivatives were found good to moderate scavengers of DPPH (IC50 2.01 ± 0.13–5.3 ± 0.11) and ABTS (IC50 = 2.34 ± 0.07–5.5 ± 0.07 μM) radicals, in comparison with standard ascorbic acid having scavenging activities with IC50 = 1.99 ± 0.09 μM, and IC50 2.03 ± 0.11 μM for DPPH and ABTS radicals. In silico molecular docking study was conducted to rationalize the binding interaction of α-amylase enzyme with ligands. Compounds were observed as mixed type inhibitors in enzyme kinetic characterization.